Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | TOP2A | P11388 | 4/20 | 0.51 |
| ▸ | TOP2B | Q02880 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL500694 | 1.00 | KDM4E (0.51) | KDM4EALDH1A1TOP2ATOP2BLMNA | |
| SCHEMBL9096418 | 1.00 | KDM4E (0.51) | KDM4EALDH1A1TOP2ATOP2BLMNA | |
| SCHEMBL28334480 | 0.90 | KDM4E (0.47) | KDM4EALDH1A1TOP2ATOP2BLMNA | |
| SCHEMBL10330768 | 0.90 | KDM4E (0.48) | KDM4EALDH1A1TOP2ATOP2BLMNA | |
| SCHEMBL2081775 | 0.84 | KDM4E (0.44) | KDM4EALDH1A1TOP2ATOP2BLMNA | |
| SCHEMBL27533526 | 0.84 | KDM4E (0.44) | KDM4EALDH1A1TOP2ATOP2BLMNA | |
| SCHEMBL2081773 | 0.84 | KDM4E (0.44) | KDM4EALDH1A1TOP2ATOP2BLMNA | |
| SCHEMBL6166633 | 0.84 | KDM4E (0.48) | KDM4EALDH1A1TOP2ATOP2BLMNA | |
| SCHEMBL27493871 | 0.84 | KDM4E (0.48) | KDM4EALDH1A1TOP2ATOP2BLMNA | |
| SCHEMBL6166631 | 0.84 | KDM4E (0.48) | KDM4EALDH1A1TOP2ATOP2BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784656-B1 | PROCESS FOR THE HYDROLYSIS OF QUINOLONE CARBOXYLIC ESTERS | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-06-28 | — | — | EP | claimed |
| US-11332444-B2 | Method for the hydrolysis of quinolonecarboxylic esters | BAYER ANIMAL HEALTH GMBH (DE) | 2022-05-17 | — | — | US | claimed |
| US-20210078950-A1 | METHOD FOR THE HYDROLYSIS OF QUINOLONECARBOXYLIC ESTERS | ELANCO ANIMAL HEALTH GMBH (DE) | 2021-03-18 | — | — | US | claimed |
| EP-1236718-B1 | Improved process for the preparation of fluoro-quinolonecarboxylic acids | BAYER CHEMICALS AG (DE) | 2004-08-11 | — | — | EP | claimed |
| US-6590101-B2 | Hydrolysis of the corresponding C1-C4-alkyl esters with addition of water, acetic acid, and sulfuric acid using a drastically reduced amount of sulfuric acid | BAYER AKTIENGESELLSCHAFT (DE) | 2003-07-08 | — | — | US | claimed |
| US-20020120138-A1 | Process for the preparation of fluoroquinolonecarboxylic acids | LANXESS DEUTSCHLAND GMBH (DE) | 2002-08-29 | — | — | US | claimed |
| EP-0191185-B1 | QUINOLINE-CARBOXYLIC ACID DERIVATIVES | DAIICHI SEIYAKU CO., LTD. (JP) | 1990-03-07 | — | — | EP | claimed |
| EP-0191185-A1 | Quinoline-carboxylic acid derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1986-08-20 | — | — | EP | claimed |
| EP-3784656-B1 | PROCESS FOR THE HYDROLYSIS OF QUINOLONE CARBOXYLIC ESTERS | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-06-28 | — | — | EP | disclosed |
| US-11332444-B2 | Method for the hydrolysis of quinolonecarboxylic esters | BAYER ANIMAL HEALTH GMBH (DE) | 2022-05-17 | — | — | US | disclosed |
| US-20210078950-A1 | METHOD FOR THE HYDROLYSIS OF QUINOLONECARBOXYLIC ESTERS | ELANCO ANIMAL HEALTH GMBH (DE) | 2021-03-18 | — | — | US | disclosed |
| US-RE41149-E1 | Stereoisomerically pure 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid or a pharmaceutically acceptable salt thereof; antibacterial agents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |
| US-RE41149-E1 | Stereoisomerically pure 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid or a pharmaceutically acceptable salt thereof; antibacterial agents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |
| US-6590101-B2 | Hydrolysis of the corresponding C1-C4-alkyl esters with addition of water, acetic acid, and sulfuric acid using a drastically reduced amount of sulfuric acid | BAYER AKTIENGESELLSCHAFT (DE) | 2003-07-08 | — | — | US | disclosed |
| EP-0704443-A2 | Quinolone and naphthyridone carboxylic acid derivatives | BAYER AG (DE) | 1996-04-03 | — | — | EP | disclosed |
| WO-1996001262-A1 | NOVEL QUINOLINE COMPOUND AND PROCESS FOR PREPARATION THEREOF | HANMI PHARMACEUTICAL CO., LTD. (KR) | 1996-01-18 | — | — | WO | disclosed |
| EP-0653425-A1 | 1-(2-Fluorocyclopropyl)-quinolone- and naphthyridone carboxylic acid derivatives, their preparation and their use as antibacterials | BAYER AG (DE) | 1995-05-17 | — | — | EP | disclosed |
| EP-0191185-B1 | QUINOLINE-CARBOXYLIC ACID DERIVATIVES | DAIICHI SEIYAKU CO., LTD. (JP) | 1990-03-07 | — | — | EP | disclosed |
| US-4871852-A | BACTERICIDES AGAINST GRAMNEGATIVE AND GRAMPOSITIVE | DAIICHI SEIYAKU CO., LTD. (JP) | 1989-10-03 | — | — | US | disclosed |
| EP-0191185-A1 | Quinoline-carboxylic acid derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120138-A1 | Process for the preparation of fluoroquinolonecarboxylic acids | ADH1C, CTRC, ADH1A | KDM4E 2934/4885ALDH1A1 124/4885TOP2A 352/4885 |
| US-20210078950-A1 | METHOD FOR THE HYDROLYSIS OF QUINOLONECARBOXYLIC ESTERS | NQO2, PGD, ALAD | KDM4E 2839/4885ALDH1A1 274/4885TOP2A 38/4885 |
| US-11332444-B2 | Method for the hydrolysis of quinolonecarboxylic esters | NQO2, PGD, ALAD | KDM4E 2839/4885ALDH1A1 274/4885TOP2A 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.